Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

2007501 citationsJournal Article

Authors

Stephen D. Silberstein · Headache Care Center

Richard B. Lipton · Yeshiva University

David W. Dodick · Mayo Clinic in Arizona

Frederick G. Freitag · Diamond Headache Clinic

Nabih M. Ramadan · Franklin University

Ninan T. Mathew · Diamond Headache Clinic

Jan Lewis Brandes ·

Abstract

Topiramate treatment at daily doses of approximately 100 mg resulted in statistically significant improvements compared with placebo in mean monthly migraine/migrainous and migraine headache days. Topiramate is safe and generally well tolerated in this group of subjects with chronic migraine, a burdensome condition with important unmet treatment needs. Safety and tolerability of topiramate were consistent with experience in previous clinical trials involving the drug.

Topics & Keywords

Migraine and Headache Studies Trigeminal Neuralgia and Treatments Sympathectomy and Hyperhidrosis Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Headache The Journal of Head and Face Pain

Volume 47, Issue 2, pp. 170-180

DOI: 10.1111/j.1526-4610.2006.00684.x

Field-Weighted Citation Impact: 19.52